๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Adjuvant targeted therapy in early breast cancer

โœ Scribed by John Mackey; Deanna McLeod; Joseph Ragaz; Karen Gelmon; Sunil Verma; Kathleen Pritchard; Kara Laing; Louise Provencher; Lauren F. Charbonneau

Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
182 KB
Volume
115
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Targeted therapy in inflammatory breast
Targeted therapy in inflammatory breast cancer
โœ Hideko Yamauchi; Naoto T. Ueno ๐Ÿ“‚ Article ๐Ÿ“… 2010 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 75 KB ๐Ÿ‘ 1 views
Adjuvant therapy for breast cancer
Adjuvant therapy for breast cancer
โœ S. Rodenhuis; E. J. T. Rutgers ๐Ÿ“‚ Article ๐Ÿ“… 2006 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 111 KB ๐Ÿ‘ 2 views

Requires sophistication

Systemic adjuvant therapy of breast canc
Systemic adjuvant therapy of breast cancer
โœ Garrett, Thomas J.; Vahdat, Linda T.; Kinne, David W. ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 52 KB ๐Ÿ‘ 2 views

Systematic adjuvant therapy has improved the outcome for women with operable breast cancer. As a result, a substantial proportion of patients with this disease are candidates for adjuvant treatment. In providing a woman with recommendations for therapy, her risk of developing recurrent breast cancer

Novel targeted therapies in inflammatory
Novel targeted therapies in inflammatory breast cancer
โœ Massimo Cristofanilli ๐Ÿ“‚ Article ๐Ÿ“… 2010 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 84 KB ๐Ÿ‘ 2 views

## Abstract Inflammatory breast cancer (IBC) accounts for 1% to 5% of all breast cancer cases. Its aggressive biology is characterized by rapid disease progression and poor prognosis. To improve and standardize therapy for IBC, development of novel therapeutics to molecular targets of IBC is key. T